Medical device companies have hardly impressed during earnings season. Revenue has fallen at many leading firms in the industry, and pricing pressures, overseas trouble, and saturated markets have left some investors wondering how much more room this industry has to grow in the near future.
Despite all this, however, leading orthopedics firms have pushed on. Companies such as Stryker and Zimmer Holdings have shown signs of hope for investors even while dealing with problems such as device recalls, but is this enough to warrant your investment in the orthopedics industry? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss what you need to know about this industry in the video below.
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out The Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
The article 1 Bright Spot in 1 Struggling Industry originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.